Defining and measuring adherence to cancer screening

Journal of Medical Screening

Volumn 23, Issue 4, 2016, Pages 179-185

  Chubak, Jessica ^a,b   Hubbard, Rebecca ^c  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; Cancer screening; Measurement

Indexed keywords

CANCER SCREENING; PRACTICE GUIDELINE; EARLY CANCER DIAGNOSIS; HEALTH SURVEY; HUMAN; NEOPLASM; PATHOLOGY; PROTOCOL COMPLIANCE; STANDARDS; UNITED STATES;

EARLY DETECTION OF CANCER; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 85011685267     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141316630766     Document Type: Article

References (23)

1. Bulliard JL, Garcia M, Blom J, et al. Sorting out measures and definitions of screening participation to improve comparability: The example of colorectal cancer. Eur J Cancer 2014; 50: 434-446.
2. Screening, Immunisations team, Health & Social Care Information Centre. Breast Screening Programme, England, statistics for 2013-14. London: Government Statistical Service, 2015.
3. Sabatino SA, White MC, Thompson TD, et al. Cancer screening test use—United States, 2013. MMWR Morb Mortal Wkly Rep 2015; 64: 464-468.
4. Centers for Disease Control and Prevention. 2013 NHIS questionnaire—sample adult. Atlanta, GA: Centers for Disease Control and Prevention, 2014, ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Survey_Questionnaires/NHIS/2013/English/qadult.pdf (accessed 25 January 2016).
5. Goulard H, Boussac-Zarebska M, Ancelle-Park R, et al. French colorectal cancer screening pilot programme: results of the first round. J Med Screen 2008; 15: 143-148.
6. National Screening Unit. The National Cervical Screening Programme (NCSP) register. Wellington, New Zealand: New Zealand Ministry of Health, https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/ncsp-register (accessed 25 January 2016).
7. Metadata Online Registry. Cervical screening data 2012-2013. Canberra, Australia: Australian Institute of Health and Welfare, http://meteor.aihw.gov.au/content/index.phtml/itemId/569669 (accessed 25 January 2016).
8. Metadata Online Registry. BreastScreen Australia data 2012-2013. Canberra, Australia: Australian Institute of Health and Welfare, http://meteor.aihw.gov.au/content/index.phtml/itemId/569662 (accessed 25 January 2016).
9. Green BB, Wang CY, Anderson ML, et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med 2013; 158(5 Pt 1): 301-311.
10. Vogt TM, Feldstein AC, Aickin M, et al. Electronic medical records and prevention quality: The prevention index. Am J Prevent Med 2007; 33: 291-296.
11. Ricardo-Rodrigues I, Jimenez-Garcia R, Hernandez-Barrera V, et al. Adherence to and predictors of participation in colorectal cancer screening with faecal occult blood testing in Spain, 2009-2011. Eur J Cancer Prev 2015; 24: 305-312.
12. Pornet C, Denis B, Perrin P, et al. Predictors of adherence to repeat fecal occult blood test in a population-based colorectal cancer screening program. Br J Cancer 2014; 111: 2152-2155.
13. Kearns B, Whyte S, Chilcott J, et al. Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme. Br J Cancer 2014; 111: 1734-1741.
14. de Munck L, Kwast A, Reiding D, et al. Attending the breast screening programme after breast cancer treatment: a population-based study. Cancer Epidemiol 2013; 37: 968-972.
15. Kapidzic A, Grobbee EJ, Hol L, et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 2014; 109: 1257-1264.
16. Lo SH, Halloran S, Snowball J, et al. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut 2015; 64: 282-291.
17. Long M, Lance T, Robertson D, et al. Colorectal cancer testing in the national veterans health administration. Dig Dis Sci 2012; 57: 288-293.
18. Martin-Lopez R, Hernandez-Barrera V, de Andres AL, et al. Trend in cervical cancer screening in Spain (2003-2009) and predictors of adherence. Eur J Cancer Prev 2012; 21: 82-88.
19. Sinicrope PS, Goode EL, Limburg PJ, et al. A population-based study of prevalence and adherence trends in average risk colorectal cancer screening, 1997-2008. Cancer Epidemiol Biomarkers Preven 2011; 21: 347-350.
20. Worthington C, McLeish K, Fuller-Thomson E. Adherence over time to cervical cancer screening guidelines: insights from the Canadian National Population Health Survey. J Womens Health (Larchmt) 2012; 21: 199-208.
21. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574. discussion 75-77.
22. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
23. Moyer VA, U. S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160: 330-338.